Cargando…

Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab

AIM: We previously reported a prospective trial evaluating the safety and efficacy of combining ipilimumab and radiation therapy in patients with metastatic melanoma. Herein, we provide a long-term update on patients with complete response (CR) or partial response (PR). PATIENTS & METHODS: We co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sodji, Quaovi H, Gutkin, Paulina M, Swetter, Susan M, Reddy, Sunil A, Hiniker, Susan M, Knox, Susan J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212514/ https://www.ncbi.nlm.nih.gov/pubmed/32399174 http://dx.doi.org/10.2217/mmt-2019-0020

Ejemplares similares

Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up
por: Gutkin, Paulina M, et al.
Publicado: (2018)

A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy
por: Knox, Susan, et al.
Publicado: (2014)

FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study
por: Hiniker, Susan M., et al.
Publicado: (2019)

Patterns of response with talimogene laherparepvec in combination with ipilimumab or ipilimumab alone in metastatic unresectable melanoma
por: Chesney, Jason, et al.
Publicado: (2019)

Photosensitive Dermatitis Induced by Nivolumab/Ipilimumab Combination Therapy in a Patient with Malignant Melanoma
por: SAKAGUCHI, Yuri, et al.
Publicado: (2020)

Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
por: Wolfe, Zachary, et al.
Publicado: (2022)

Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma
por: Jeter, Joanne M., et al.
Publicado: (2012)

Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
por: Postow, Michael A., et al.
Publicado: (2015)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020
por: Qian, Mollie F, et al.
Publicado: (2022)

Ipilimumab cystic hypophysitis mimicking metastatic melanoma
por: Wallace, John, et al.
Publicado: (2018)

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
por: Seremet, Teofila, et al.
Publicado: (2016)

Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition
por: Sodji, Quaovi, et al.
Publicado: (2017)

Inflammation, Fibrosis and Cancer: Mechanisms, Therapeutic Options and Challenges
por: Wu, Bocheng, et al.
Publicado: (2022)

Ipilimumab and radiation therapy for melanoma brain metastases
por: Silk, Ann W, et al.
Publicado: (2013)

Predictors of clinical response to immunotherapy with or without radiotherapy
por: Hiniker, Susan M., et al.
Publicado: (2015)

Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma
por: Hanley, T, et al.
Publicado: (2018)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Case Report: Thrombotic-Thrombocytopenic Purpura Following Ipilimumab and Nivolumab Combination Immunotherapy for Metastatic Melanoma
por: Mullally, W. J., et al.
Publicado: (2022)

Profile of ipilimumab and its role in the treatment of metastatic melanoma
por: Patel, Sapna P, et al.
Publicado: (2011)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Predictors of toxicity for metastatic melanoma patients treated with ipilimumab
por: Valpione, Sara, et al.
Publicado: (2015)

Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma
por: Formozo, A. A., et al.
Publicado: (2021)

Acute visual loss after ipilimumab treatment for metastatic melanoma
por: Wilson, Melissa A., et al.
Publicado: (2016)

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
por: Wolchok, Jedd D., et al.
Publicado: (2022)

Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
por: Mullinax, John E., et al.
Publicado: (2018)

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
por: Gibney, Geoffrey T., et al.
Publicado: (2019)

Successful Treatment of Multiple Metastatic Melanoma with Nivolumab, Ipilimumab plus Denosumab Combined Therapy
por: Yoshida, Saaya, et al.
Publicado: (2019)

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
por: Feng, Yan, et al.
Publicado: (2014)

Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review
por: Chicas-Sett, Rodolfo, et al.
Publicado: (2017)

Use of Audiovisual Assisted Therapeutic Ambience in Radiotherapy (AVATAR) for Anesthesia Avoidance in a Pediatric Patient With Down Syndrome
por: Gutkin, Paulina M., et al.
Publicado: (2020)

Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics
por: Rossfeld, Kara, et al.
Publicado: (2017)

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report
por: He, Kewen, et al.
Publicado: (2023)

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
por: Chmielowski, Bartosz
Publicado: (2013)

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
por: Montes, Vera, et al.
Publicado: (2018)

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma
por: Chu, Michael P., et al.
Publicado: (2020)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Use of ipilimumab in the treatment of melanoma
por: Acharya, Utkarsh H, et al.
Publicado: (2013)

Ipilimumab: Melanoma and beyond
por: Patel, Vishal, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tqob785fvqhvjpume4kpd8tuf7